Updates in Therapeutics for Parkinson’s Disease

The speaker was Gaurav Chattree, MD, movement disorder specialist at Stanford. He addressed the "phase 3" or "almost phase 3" research pipeline for disease-modification treatments and for symptomatic therapies.
Visit the Palo Alto Parkinson's Support Group
med.stanford.edu/parkinsons/n...
Stanford's APDA Information & Referral Center and Stanford Parkinson's Community Outreach coordinate a local Parkinson's Disease (PD) support group in Palo Alto. Since March 2021, we meet virtually, highlighting local resources, Stanford healthcare professionals, and Stanford research.

[@mantaslukosiunas6248]

Thanks for great insights!
About buntanetap - they had 520 ptients phase 3, 6momths trial enrolled in record speed. Interim analysis done at 2 months mark said - go ahead, do not increase trial size. They already completed this trial. After first cleaning jobs cro cleaning center made some mistakes and found that 40-50 patients had low buntanetap plasma levels and company had to exclude those, or go ahead with them before database lock.
Also, internet is full of anectodal responses how Buntanetap changed prkinsons ptients lifes. We will see Parkinsons results in June.
Their alzheimwrs phase2/3 with 320 patients 3 motnhs study comes out this konth too!! Data is already cleaned

[@chinko1953]

Ambroxyl , a common OVER THE COUNTER cough medicine in europe, is an orphan because it is not patentable by big pharm. Results in the UK seem very encouraging. I would love to try it. Unfortunately not sold in North America..

[@alaneverett9767]

Order it online

[@shaynadavidovhansonrealtor]

Interesting